
The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency procedures.
The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency procedures.
© 2023 LBNN - All rights reserved.